Drug intelligence / Profile preview

18F-NYM124

Development stage
Unknown
Lead developer
Norroy Bioscience
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
Administration
Intravenous
01

Overview

18F-NYM124 is a novel, small-molecule radiopharmaceutical designed for positron emission tomography (PET) imaging of carbonic anhydrase IX (CAIX)-expressing tumors. Developed by Norroy Bioscience, the tracer is primarily being evaluated for the non-invasive detection, staging, and characterization of clear cell renal cell carcinoma (ccRCC) and indeterminate renal masses. Carbonic anhydrase IX is a tumor-associated antigen highly overexpressed in ccRCC due to hypoxia-inducible factor (HIF) pathway activation. By targeting CAIX with high affinity, 18F-NYM124 enables high-contrast molecular imaging with favorable tumor-to-background ratios and rapid systemic clearance, offering a potential diagnostic alternative or complement to conventional 18F-FDG PET/CT.

Other names
[18F]F-NYM124[18F]NYM124
02

Targets

CA9 (Carbonic anhydrase IX)

Beyond the preview

Go deeper on 18F-NYM124.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 18F-NYM124.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call